SG11202012697QA - Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor - Google Patents
Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitorInfo
- Publication number
- SG11202012697QA SG11202012697QA SG11202012697QA SG11202012697QA SG11202012697QA SG 11202012697Q A SG11202012697Q A SG 11202012697QA SG 11202012697Q A SG11202012697Q A SG 11202012697QA SG 11202012697Q A SG11202012697Q A SG 11202012697QA SG 11202012697Q A SG11202012697Q A SG 11202012697QA
- Authority
- SG
- Singapore
- Prior art keywords
- krasg12c
- mutein
- pyridone
- inhibitor
- pyrimidine derivative
- Prior art date
Links
- RAJOAWNHLQRLSR-UHFFFAOYSA-N 1H-pyridin-2-one pyrimidine Chemical class C1=CN=CN=C1.OC1=CC=CC=N1 RAJOAWNHLQRLSR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810055396 | 2018-01-19 | ||
| CN201810712103 | 2018-06-29 | ||
| PCT/CN2019/072393 WO2019141250A1 (en) | 2018-01-19 | 2019-01-18 | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012697QA true SG11202012697QA (en) | 2021-02-25 |
Family
ID=67301292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012697QA SG11202012697QA (en) | 2018-01-19 | 2019-01-18 | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
| SG10202102462SA SG10202102462SA (en) | 2018-01-19 | 2019-01-18 | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202102462SA SG10202102462SA (en) | 2018-01-19 | 2019-01-18 | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11453667B2 (en) |
| EP (2) | EP3842433B1 (en) |
| JP (2) | JP7289839B2 (en) |
| CN (4) | CN112442031B (en) |
| ES (1) | ES2969284T3 (en) |
| SG (2) | SG11202012697QA (en) |
| WO (1) | WO2019141250A1 (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202012697QA (en) * | 2018-01-19 | 2021-02-25 | Medshine Discovery Inc | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
| CN113227089B (en) | 2018-10-31 | 2024-07-05 | 吉利德科学公司 | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors |
| CN117105933A (en) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | Substituted 6-azabenzimidazole compounds with HPK1 inhibitory activity |
| CN113382774A (en) | 2019-02-12 | 2021-09-10 | 诺华股份有限公司 | Pharmaceutical combination comprising TNO155 and KRASG12C inhibitors |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| BR112022005193A2 (en) * | 2019-09-20 | 2022-08-16 | Shanghai Jemincare Pharmaceuticals Co Ltd | MOLTED PYRIDONE COMPOUND, METHOD OF PREPARING IT AND USE THEREOF |
| US20220389021A1 (en) * | 2019-09-29 | 2022-12-08 | Beigene, Ltd. | Inhibitors of kras g12c |
| CN113286794B (en) * | 2019-11-04 | 2024-03-12 | 北京加科思新药研发有限公司 | KRAS mutant protein inhibitors |
| CN112824410A (en) * | 2019-11-21 | 2021-05-21 | 苏州泽璟生物制药股份有限公司 | Aza-heptacyclic inhibitor and preparation method and application thereof |
| IL293962B2 (en) | 2019-12-19 | 2025-10-01 | Jacobio Pharmaceuticals Co Ltd | Kras mutant protein inhibitors |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CN113527293B (en) * | 2020-04-20 | 2023-09-08 | 苏州璞正医药有限公司 | KRAS G12C mutant protein inhibitor, pharmaceutical composition, preparation method and application thereof |
| CN111423366B (en) * | 2020-04-28 | 2022-05-27 | 山东汇海医药化工有限公司 | Preparation method of pirfenidone |
| CN113880827B (en) * | 2020-07-03 | 2024-10-01 | 苏州闻天医药科技有限公司 | Compound for inhibiting KRASG12C mutant protein and preparation method and application thereof |
| WO2022048545A1 (en) * | 2020-09-01 | 2022-03-10 | 勤浩医药（苏州）有限公司 | Crystal form of pyridopyrimidine compound |
| US20250268901A1 (en) * | 2020-09-11 | 2025-08-28 | Medshine Discovery Inc. | Crystal form of azetidine-substituted compound |
| IL301524A (en) | 2020-09-23 | 2023-05-01 | Erasca Inc | Pyridones and tricyclic pyrimidones |
| WO2022121839A1 (en) * | 2020-12-08 | 2022-06-16 | 上海和誉生物医药科技有限公司 | Pyrido[2,3-d]pyrimidin-2(1h)-one derivative, and preparation method therefor and application thereof |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022222871A1 (en) * | 2021-04-21 | 2022-10-27 | Beijing Innocare Pharma Tech Co., Ltd. | Heterocyclic compounds as kras g12c inhibitors |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| TW202317100A (en) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
| TW202327569A (en) | 2021-09-01 | 2023-07-16 | 瑞士商諾華公司 | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| EP4389751A1 (en) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN118355019B (en) | 2022-01-21 | 2025-02-14 | 祐森健恒生物医药（上海）有限公司 | Benzopyrimidine compounds and their applications |
| WO2023173017A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| CN117430620A (en) * | 2022-07-22 | 2024-01-23 | 上海医药集团股份有限公司 | Pyrimidine ring compounds, their intermediates, their pharmaceutical compositions and their applications |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| CN120981456A (en) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | Heterocyclic compounds and their use |
| WO2025007000A1 (en) | 2023-06-30 | 2025-01-02 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| WO2025067453A1 (en) * | 2023-09-27 | 2025-04-03 | 健艾仕生物医药有限公司 | Pharmaceutical combination comprising kras inhibitor, composition comprising same, and use thereof |
| WO2025067459A2 (en) | 2023-09-29 | 2025-04-03 | D3 Bio (Wuxi) Co., Ltd. | Therapies for the treatment of cancer |
| WO2025146477A1 (en) | 2024-01-04 | 2025-07-10 | Muna Therapeutics Aps | 2-azetidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-7,8-dihydropyrimido[5,4-d]pyrimidine derivatives derivatives as trem2 modulators for the treatment of neurodegenerative diseases |
| TW202535410A (en) | 2024-01-04 | 2025-09-16 | 丹麥商穆納醫療有限責任公司 | Trem2 modulators |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025230971A1 (en) | 2024-04-30 | 2025-11-06 | Kumquat Biosciences Inc. | Macrocyclic heterocycles as anticancer agents |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3560453B1 (en) * | 2012-03-30 | 2020-11-25 | Orthodontic Research and Development, S.L. | Method of assembling a distalizer |
| UA119971C2 (en) * | 2013-10-10 | 2019-09-10 | Араксіс Фарма Ллк | Inhibitors of kras g12c |
| EP3280708B1 (en) * | 2015-04-10 | 2021-09-01 | Araxes Pharma LLC | Substituted quinazoline compounds and methods of use thereof |
| ES2856880T3 (en) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | KRAS Condensed Tricyclic Inhibitors and Methods of Using Them |
| EA038635B9 (en) | 2015-11-16 | 2021-10-26 | Араксис Фарма Ллк | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) * | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| AU2017266911B2 (en) | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
| US10280172B2 (en) * | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| MY196830A (en) | 2016-12-22 | 2023-05-03 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| WO2018140600A1 (en) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| US20200109153A1 (en) | 2017-05-11 | 2020-04-09 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| SG11202012697QA (en) * | 2018-01-19 | 2021-02-25 | Medshine Discovery Inc | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
-
2019
- 2019-01-18 SG SG11202012697QA patent/SG11202012697QA/en unknown
- 2019-01-18 CN CN202011378153.1A patent/CN112442031B/en active Active
- 2019-01-18 JP JP2020539829A patent/JP7289839B2/en active Active
- 2019-01-18 WO PCT/CN2019/072393 patent/WO2019141250A1/en not_active Ceased
- 2019-01-18 CN CN202110310525.5A patent/CN113121530B/en active Active
- 2019-01-18 EP EP21155251.8A patent/EP3842433B1/en active Active
- 2019-01-18 EP EP19740933.7A patent/EP3741756B1/en active Active
- 2019-01-18 CN CN201980009147.8A patent/CN111630053A/en active Pending
- 2019-01-18 US US16/962,951 patent/US11453667B2/en active Active
- 2019-01-18 CN CN202011378149.5A patent/CN112442030B/en active Active
- 2019-01-18 ES ES19740933T patent/ES2969284T3/en active Active
- 2019-01-18 SG SG10202102462SA patent/SG10202102462SA/en unknown
-
2021
- 2021-01-27 US US17/159,928 patent/US11655248B2/en active Active
- 2021-02-05 JP JP2021017606A patent/JP7352587B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021510721A (en) | 2021-04-30 |
| US20210371411A1 (en) | 2021-12-02 |
| ES2969284T3 (en) | 2024-05-17 |
| CN113121530B (en) | 2022-08-05 |
| CN112442030A (en) | 2021-03-05 |
| CN112442031A (en) | 2021-03-05 |
| CN112442030B (en) | 2022-09-27 |
| WO2019141250A1 (en) | 2019-07-25 |
| JP2021091691A (en) | 2021-06-17 |
| US11655248B2 (en) | 2023-05-23 |
| CN112442031B (en) | 2022-07-12 |
| EP3842433B1 (en) | 2023-11-01 |
| CN113121530A (en) | 2021-07-16 |
| EP3741756B1 (en) | 2023-11-01 |
| EP3741756A1 (en) | 2020-11-25 |
| EP3842433A1 (en) | 2021-06-30 |
| EP3741756A4 (en) | 2020-12-09 |
| CN111630053A (en) | 2020-09-04 |
| SG10202102462SA (en) | 2021-04-29 |
| JP7352587B2 (en) | 2023-09-28 |
| US20210147418A1 (en) | 2021-05-20 |
| US11453667B2 (en) | 2022-09-27 |
| JP7289839B2 (en) | 2023-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202102462SA (en) | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor | |
| IL275207A (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| IL277455A (en) | Aminopyrimidine derivatives as ctps1 inhibitors | |
| PL4073065T3 (en) | New methylquinazolinone derivatives | |
| IL269803A (en) | 6-pyrimidin-isoindole derivative as erk1/2 inhibitor | |
| GB202201999D0 (en) | Interleukin-2 Derivative | |
| SG11202004918XA (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| HUE070924T2 (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| SG11202101622VA (en) | Novel quinoline derivative inhibitor | |
| PL4077334T3 (en) | Furoindazole derivatives | |
| IL283990A (en) | Substituted oxopyridine derivatives | |
| IL290815A (en) | Alpha-d-galactopyranoside derivatives | |
| IL281634A (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
| IL290964A (en) | 2-aminoquinazolinone derivative | |
| SG11202012594RA (en) | Spirochromane derivatives | |
| LT3796975T (en) | Sulfonylaminobenzamide derivatives | |
| SG11202007979UA (en) | Dihydrochromene derivative | |
| SG11202006837XA (en) | Dihydroindolizinone derivative | |
| GB201919210D0 (en) | Dihydro-cyclopenta-isoquinoline derivatives | |
| ZA202200181B (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201806948D0 (en) | Derivatives |